UCB 6352

Drug Profile

UCB 6352

Alternative Names: Anti-CSF-1R monoclonal antibody - Syndax Pharmaceuticals; SNDX-6352; UCB 6352

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Developer Syndax Pharmaceuticals; UCB
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Macrophage colony stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer; Solid tumours

Most Recent Events

  • 01 Sep 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Late-stage disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater) in USA (IV) (NCT03238027)
  • 31 Aug 2017 Syndax Pharmaceuticals plans a phase I trial for Solid tumour (Second-line therapy or greater, Metastatic disease, Late-stage disease, Recurrent, Inoperable/Unresectable) in USA in September 2017 (NCT03238027)
  • 08 May 2017 Syndax plans a multiple ascending dose (MAD) trial for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top